VF5 Stock Overview
Ondine Biomedical Inc., a Life sciences company, engages in the research, development, and commercialization of antimicrobial photodisinfection therapies in Canada and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
Ondine Biomedical Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.044 |
| 52 Week High | UK£0.19 |
| 52 Week Low | UK£0.043 |
| Beta | -0.15 |
| 1 Month Change | -50.56% |
| 3 Month Change | -55.33% |
| 1 Year Change | -76.96% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -93.16% |
Recent News & Updates
Recent updates
Shareholder Returns
| VF5 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -17.8% | 2.6% | 1.2% |
| 1Y | -77.0% | -8.3% | 2.0% |
Return vs Industry: VF5 underperformed the German Medical Equipment industry which returned -8.3% over the past year.
Return vs Market: VF5 underperformed the German Market which returned 2% over the past year.
Price Volatility
| VF5 volatility | |
|---|---|
| VF5 Average Weekly Movement | 11.2% |
| Medical Equipment Industry Average Movement | 4.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: VF5's share price has been volatile over the past 3 months.
Volatility Over Time: VF5's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | n/a | Carolyn Cross | www.ondinebio.com |
Ondine Biomedical Inc., a Life sciences company, engages in the research, development, and commercialization of antimicrobial photodisinfection therapies in Canada and internationally. Its product platform is Photodisinfection, a topical light-based antimicrobial technology that eliminates harmful pathogens. The company’s lead product is Steriwave, a photodisinfection-based medical device that eliminates harmful nasal pathogens, which leads to healthcare-associated infections.
Ondine Biomedical Inc. Fundamentals Summary
| VF5 fundamental statistics | |
|---|---|
| Market cap | €14.61m |
| Earnings (TTM) | -€12.77m |
| Revenue (TTM) | €548.86k |
26.6x
P/S Ratio-1.1x
P/E RatioIs VF5 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VF5 income statement (TTM) | |
|---|---|
| Revenue | CA$804.00k |
| Cost of Revenue | CA$410.00k |
| Gross Profit | CA$394.00k |
| Other Expenses | CA$19.10m |
| Earnings | -CA$18.70m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.082 |
| Gross Margin | 49.00% |
| Net Profit Margin | -2,326.12% |
| Debt/Equity Ratio | 6.8% |
How did VF5 perform over the long term?
See historical performance and comparison